David Arkowitz Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for David Arkowitz.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of David Arkowitz. David Arkowitz is Chief Financial Officer in IDENIX PHARMACEUTICALS INC ($IDIX) and Chief Financial Officer in Flexion Therapeutics Inc ($FLXN) and Director in PROTEOSTASIS THERAPEUTICS, INC. ($PTI) and Director in Spring Bank Pharmaceuticals, Inc. ($SBPH).
Latest Insider Trading Transactions of David Arkowitz
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, SBPH, FLXN, IDIX, YMTX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 07 2021 | SBPH | F-star Therapeutic ... | Arkowitz David | Director | Option Exercise | A | 6.88 | 20,000 | 137,600 | 20,000 | |
| May 12 2021 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Sell | S | 7.23 | 2,229 | 16,116 | 220,719 | 222.9 K to 220.7 K (-1.00 %) |
| Jan 07 2021 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Sell | S | 11.13 | 6,073 | 67,592 | 151,048 | 157.1 K to 151 K (-3.87 %) |
| Dec 28 2020 | PTI | YUMANITY THERAPEUT ... | Arkowitz David | Director | Grant | A | 23.00 | 4,347 | 99,981 | 4,347 | 0 to 4.3 K |
| Jul 20 2020 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Grant | A | 0.00 | 38,750 | 0 | 157,121 | 118.4 K to 157.1 K (+32.74 %) |
| Jul 20 2020 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Grant | A | 0.00 | 38,750 | 0 | 157,121 | 118.4 K to 157.1 K (+32.74 %) |
| Jul 01 2020 | PTI | PROTEOSTASIS THERA ... | Arkowitz David | Director | Option Exercise | A | 1.39 | 17,400 | 24,186 | 17,400 | |
| Jun 25 2020 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 1.60 | 7,500 | 12,000 | 7,500 | |
| Jun 24 2020 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Grant | A | 10.83 | 1,303 | 14,111 | 118,371 | 117.1 K to 118.4 K (+1.11 %) |
| May 11 2020 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Sell | S | 10.88 | 2,413 | 26,253 | 117,068 | 119.5 K to 117.1 K (-2.02 %) |
| Jan 07 2020 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Sell | S | 0.00 | 3,095 | 0 | 88,481 | 91.6 K to 88.5 K (-3.38 %) |
| Jan 02 2020 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 0.00 | 9,098 | 0 | 37,929 | 28.8 K to 37.9 K (+31.56 %) |
| Oct 01 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 0.00 | 4,179 | 0 | 28,831 | 24.7 K to 28.8 K (+16.95 %) |
| Oct 01 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 0.00 | 4,179 | 0 | 28,831 | 24.7 K to 28.8 K (+16.95 %) |
| Jul 11 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 4.62 | 7,500 | 34,650 | 7,500 | |
| Jul 11 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 4.62 | 7,500 | 34,650 | 7,500 | |
| Jul 01 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 0.00 | 3,896 | 0 | 24,652 | 20.8 K to 24.7 K (+18.77 %) |
| Jun 24 2019 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Grant | A | 9.81 | 2,152 | 21,111 | 91,576 | 89.4 K to 91.6 K (+2.41 %) |
| Jun 03 2019 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Buy | P | 11.05 | 2,500 | 27,627 | 89,424 | 86.9 K to 89.4 K (+2.88 %) |
| May 15 2019 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Buy | P | 11.99 | 4,000 | 47,960 | 86,924 | 82.9 K to 86.9 K (+4.82 %) |
| May 09 2019 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Sell | S | 10.06 | 2,248 | 22,615 | 82,924 | 85.2 K to 82.9 K (-2.64 %) |
| Mar 08 2019 | PTI | PROTEOSTASIS THERA ... | Arkowitz David | Director | Option Exercise | A | 4.07 | 30,600 | 124,542 | 30,600 | |
| Mar 05 2019 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Option Exercise | A | 14.75 | 18,000 | 265,500 | 18,000 | |
| Mar 05 2019 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Grant | A | 0.00 | 36,000 | 0 | 85,172 | 49.2 K to 85.2 K (+73.21 %) |
| Jan 04 2019 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Buy | J | 10.48 | 922 | 9,663 | 49,172 | 48.3 K to 49.2 K (+1.91 %) |
| Nov 13 2018 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Buy | P | 16.56 | 4,000 | 66,222 | 48,250 | 44.3 K to 48.3 K (+9.04 %) |
| Aug 10 2018 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Buy | P | 23.42 | 4,000 | 93,680 | 44,250 | 40.3 K to 44.3 K (+9.94 %) |
| Jun 19 2018 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 13.99 | 5,500 | 76,945 | 5,500 | |
| Jun 04 2018 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Option Exercise | A | 27.01 | 115,000 | 3,106,150 | 115,000 | |
| Jun 04 2018 | FLXN | Flexion Therapeuti ... | Arkowitz David | Chief Financial Off ... | Grant | A | 0.00 | 30,000 | 0 | 40,250 | 10.3 K to 40.3 K (+292.68 %) |
| Aug 07 2017 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Buy | P | 12.24 | 2,300 | 28,152 | 19,386 | 17.1 K to 19.4 K (+13.46 %) |
| Aug 07 2017 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Buy | P | 12.25 | 200 | 2,450 | 17,086 | 16.9 K to 17.1 K (+1.18 %) |
| Jun 16 2017 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 14.27 | 5,500 | 78,485 | 5,500 | |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 10.79 | 4,386 | 47,325 | 4,386 | |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 9.12 | 4,386 | 40,000 | 16,886 | 12.5 K to 16.9 K (+35.09 %) |
| Jul 29 2016 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 9.05 | 5,500 | 49,775 | 5,500 | |
| Mar 14 2007 | IDIX | IDENIX PHARMACEUTI ... | Arkowitz David | Chief Financial Off ... | Option Exercise | A | 8.12 | 40,000 | 324,800 | 40,000 | |
| Mar 09 2006 | IDIX | IDENIX PHARMACEUTI ... | Arkowitz David | Chief Financial Off ... | Option Exercise | A | 21.11 | 30,000 | 633,300 | 30,000 | |
| Mar 02 2005 | IDIX | IDENIX PHARMACEUTI ... | Arkowitz David | Chief Financial Off ... | Option Exercise | A | 19.14 | 30,000 | 574,200 | 30,000 | |
| Jul 29 2004 | IDIX | IDENIX PHARMACEUTI ... | Arkowitz David | Chief Financial Off ... | Option Exercise | A | 12.05 | 30,000 | 361,500 | 30,000 | |
| Jul 29 2004 | IDIX | IDENIX PHARMACEUTI ... | Arkowitz David | Chief Financial Off ... | Buy | P | 14.00 | 8,000 | 112,000 | 8,000 | 0 to 8 K |
Page: 1